Diethyldithiocarbamate chemoprotection of carboplatin-induced hematological toxicity
- 40 Downloads
Carboplatin therapy has a more favorable toxicity profile than cisplatin and, given in appropriate doses, is equivalent in efficacy to cisplatin for suboptimal ovarian cancer. However myelosuppression frequently curtails therapy with carboplatin. Diethyldithiocarbamate (DDTC) is a thiol compound and heavy-metal-chelating agent that has been shown to protect against carboplatin-induced bone marrow suppression in animal models. This pilot study was undertaken to evaluate the ability of DDTC to ameliorate the degree and/or duration of myelosuppression from carboplatin chemotherapy in patients with relapsed ovarian cancer. Ten patients who had previously demonstrated a response to platinum-based chemotherapy, were treated with single-agent intravenous carboplatin 400 mg/m2 administered over 30–60 min every 4 weeks. Patients received their first cycle of carboplatin without DDTC, and their second cycle with DDTC. DDTC at 600 mg/m2 was infused over 3 h commencing 30 min prior to carboplatin and was well tolerated. Treatment with DDTC did not decrease the degree of leukopenia or thrombocytopenia associated with carboplatin chemotherapy, nor did it decrease the duration of myelosuppression. This clinical study demonstrates no evidence of a bone-marrow-protective effect for this dose and schedule of DDTC in patients receiving carboplatin chemotherapy.
Key wordsDiethyldithiocarbamate chemoprotection Hematological toxicity Carboplatin chemotherapy
Unable to display preview. Download preview PDF.
- Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA, Jolles CJ (1989) Improved therapeutic index of carboplatin plus cyclophosphamide vs cisplatin plus cyclophosphamide: final report of a phase III randomized trial in stages III–IV ovarian cancer. J Clin Oncol 10:706–717Google Scholar
- Hersh EM, Petersen E, Yocum DE, Gorman RS, Darragh JM (1987) Dose response study of diethyldithiocarbamate in patients with ARC and Aids. Proc Am Soc Clin Oncol 6:2Google Scholar
- Paredes J, Hong WK, Felder TB, Dimery IW, Choski AJ, Newan RA, Castellanos AM, Robbins KT, McCarthy K, Atkinson N, Kramer AM, Hersh EV, Goepert H (1988) Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma on the head and neck. J Clin Oncol 6:955–964PubMedGoogle Scholar
- Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O'Connell G, MacLean G, Kirk ME, Canetta R, Koski B, Shelley W, Zee B, Pater J (1992) Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the national cancer institute of Canada clinical trials group. J Clin Oncol 10:718–726PubMedGoogle Scholar